Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
NCT07372287

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

Led by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Updated on 2026-04-28

230

Participants Needed

1

Research Sites

166 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.

CONDITIONS

Official Title

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Understand the study and voluntarily sign the informed consent form.
  • Age 18 to 80 years old, male or female, weighing at least 40 kg.
  • Diagnosed with asthma for at least 1 year.
  • Pre-bronchodilator FEV1 at least 80% of the normal predicted value.
  • Positive bronchodilation test within 24 months before informed consent or at screening.
  • Receiving medium-to-high dose inhaled corticosteroids combined with at least one control drug for at least 3 months, with stable treatment for 1 month before consent.
  • Asthma Control Questionnaire-5 (ACQ-6) score of 1.5 or higher.
  • Experienced at least one severe asthma exacerbation within 12 months before consent and none within 30 days before consent.
  • At least 80% compliance with usual asthma controller therapy during screening.
  • Willing to use effective contraception from consent until 3 months after last dose.
Not Eligible

You will not qualify if you...

  • Chronic obstructive pulmonary disease (COPD) without asthma or other lung diseases impairing lung function.
  • Systemic diseases or infections causing elevated eosinophils not treated or unresponsive.
  • Prior autoimmune disease or biologic/immunosuppressive treatment within 8 weeks or 5 half-lives before consent.
  • History of immunosuppression or frequent/recurrent infections.
  • History of cancer.
  • Severe or uncontrolled medical conditions such as neurological disease, severe mental disorder, or poorly controlled diabetes.
  • Active or recent infections requiring treatment within 4 weeks before randomization.
  • Severe cardiovascular disease or ECG abnormalities during screening.
  • Major surgery requiring anesthesia or hospitalization within 8 weeks before consent.
  • Use of biological agents for similar purposes within 4 months or 5 half-lives before consent.
  • Participation in other clinical trials within 3 months before consent or during follow-up.
  • Received immune globulin or blood products within 30 days before consent.
  • Use of systemic corticosteroids for non-asthma reasons within 8 weeks before randomization.
  • Received live or attenuated vaccines within 3 months before consent.
  • Started desensitization therapy within 3 months before consent.
  • Underwent bronchial thermoplasty within 12 months before consent.
  • Current smokers or recent quitters with significant smoking history.
  • Positive tests for certain infections or abnormal liver/kidney function.
  • Allergy or intolerance to CM326 or placebo components.
  • Heavy alcohol use within 3 months before screening.
  • History of drug abuse within 5 years before consent.
  • Pregnancy, lactation, or positive pregnancy test.
  • Any condition preventing completion of the study as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ruijin Hospital, Shanghai Jiao tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Information Group officer

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here